Trial reportMarine drugs2017
Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial.
Trial report in Marine drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it.
- What Is the Role of Nutraceutical Products in Cancer Patients? A Systematic Review of Randomized Clinical Trials.Nutrients · 2023Pooled it
- Fucoidan Improves Tumour Control and Liver Function in TACE for Unresectable Hepatocellular Carcinoma: A Randomised Trial.Liver international : official journal of the International Association for the Study of the Liver · 2025Trial
- The Auxiliary Effects of Low-Molecular-Weight Fucoidan in Locally Advanced Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy Before Surgery: A Double-Blind, Randomized, Placebo-Controlled Study.Integrative cancer therapiesTrial
- Fucoidan-Based Combination Strategies in Cancer Therapy: Biological Basis, Current Evidence, and Future Perspectives.International journal of molecular sciences · 2026Review
- Seaweed bioactives: A comprehensive review of their nutritional, medicinal, and functional roles.iScience · 2026Review
- Fucoidan: An Update on Function, Role in Human Health and Applications.Chemical biology & drug design · 2026Review
- Review
- Navigating the challenges in fucoidan industrialization: factors affecting biological activity and strategies for application of functional material.Food science and biotechnology · 2026Review
- Effects of dietary fucoidan and exercise on the gut microbiome, fecal metabolome, and tumor-related responses in a murine colorectal cancer model.Frontiers in cellular and infection microbiology · 2026Article
- Fucoidan for Lung Cancer Therapy: A Review of Classification, Mechanisms, and Preclinical Studies.ACS omega · 2025Review
- Fucoidan in cancer therapy: from biomedical application to medicinal chemistry approach.Journal of materials science. Materials in medicine · 2025Review
- Natural product-based nanotechnological formulations for colorectal cancer treatment.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Herbal Medicine for Colorectal Cancer Treatment: Molecular Mechanisms and Clinical Applications.Cell proliferation · 2025Review
- Marine Oligo-Fucoidan as a Safe Functional Food for Managing Uterine Fibroids: Results from a Pilot Randomized Controlled Trial.Biomedicines · 2025Article
- The Origin, Properties, Structure, Catalytic Mechanism, and Applications of Fucoidan-Degrading Enzymes.Marine drugs · 2025Review
- Article
- Fucoidan as a therapeutic agent for ulcerative colitis: mechanisms of action and modulation of the gut microbiota.Frontiers in cellular and infection microbiology · 2025Review
- Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy.Military Medical Research · 2024Review
- Elimination of Ethanol for the Production of Fucoidans from Brown Seaweeds: Characterization and Bioactivities.Marine drugs · 2024Article
- Lipid- and glucose-lowering effects of Rhamnan sulphate fromFood science & nutrition · 2024Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLow-molecular-weight fucoidan (LMF) is widely used as a food supplement for cancer patients. However, all of the studies are in vitro or were conducted using mice. Therefore, powerful clinical evidence for LMF use is relatively weak. This study aimed to evaluate the efficacy of LMF as a supplemental therapy to chemo-target agents in metastatic colorectal cancer (mCRC) patients.
methodsWe conducted a prospective, randomized, double-blind, controlled trial to evaluate the efficacy of LMF as a supplemental therapy to chemotarget agents in patients with metastatic colorectal cancer (mCRC). Sixty eligible patients with mCRC were included. Finally, 54 patients were enrolled, of whom 28 were included in the study group and 26 in the control group. The primary endpoint was the disease control rate (DCR), and secondary endpoints included the overall response rate (ORR), progression-free survival (PFS), overall survival (OS), adverse effects (AEs), and quality of life (QOL).
resultsThe DCRs were 92.8% and 69.2% in the study and control groups, respectively (
conclusionThis is the first clinical trial evaluating the efficacy of LMF as a supplemental therapy in the management of patients with mCRC. The results indicate that LMF combined with chemotarget agents significantly improved the DCR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.